From Editor-in-Chief

Editor-in-Chief Message 1st 2nd 3rd 4th

Photo:Kouichi Yoshinari

Prof. Kouichi Yoshinari, Ph.D.
School of Pharmaceutical Sciences,
University of Shizuoka


On December 2017, I became the Editor-in-Chief of Drug Metabolism and Pharmacokinetics (DMPK), the official journal of the Japanese Society for the Study of Xenobiotics (JSSX). Professors Masahiro Hayashi, Kan Chiba, Ikumi Tamai and Hiroshi Yamazaki served as four-year terms of office, and I am the fifth Editor-in-Chief.

DMPK was born in 2002 when “Yakubutsudoutai”, which had been written in Japanese, became an English-based journal. It publishes volume 34 in 2019. During the last decade, we have introduced the electronic submission system, registered DMPK with PubMed, obtained the impact factor, and introduced the early on-line publication system of the accepted manuscripts. In addition, we have been publishing the abstracts of the annual meetings of the International Society for the Study of Xenobiotics (ISSX) as Supplements at the beginning of every year since 2017. Through these activities, we have been working on establishing our journal’s position as an international scientific journal.

In addition to Regular Articles, Notes and invited Reviews, DMPK publishes Letters to the Editors and Commentaries. We welcome your submissions of Letters and Commentaries. I hope that DMPK will become a place for scientific discussion.

To increase international awareness of DMPK, selecting an attractive and timely topic of the theme issue, which is published as the first issue every volume (year), is very important. I also believe that strengthening the Editorial Advisory Board system is necessary for prompt review and publication of articles. These important issues are being promoted in cooperation with the DMPK activation committee set up within JSSX. Finally, there is no doubt that comments and suggestions from readers and authors of DMPK itself are necessary to make DMPK a better international journal. I would like to ask your cooperation with us for further development of DMPK.